363 related articles for article (PubMed ID: 29311309)
1. Signaling by the Epstein-Barr virus LMP1 protein induces potent cytotoxic CD4
Choi IK; Wang Z; Ke Q; Hong M; Qian Y; Zhao X; Liu Y; Kim HJ; Ritz J; Cantor H; Rajewsky K; Wucherpfennig KW; Zhang B
Proc Natl Acad Sci U S A; 2018 Jan; 115(4):E686-E695. PubMed ID: 29311309
[TBL] [Abstract][Full Text] [Related]
2. LMP1-deficient Epstein-Barr virus mutant requires T cells for lymphomagenesis.
Ma SD; Xu X; Plowshay J; Ranheim EA; Burlingham WJ; Jensen JL; Asimakopoulos F; Tang W; Gulley ML; Cesarman E; Gumperz JE; Kenney SC
J Clin Invest; 2015 Jan; 125(1):304-15. PubMed ID: 25485679
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of EBV inducing anti-tumour immunity and its therapeutic use.
Choi IK; Wang Z; Ke Q; Hong M; Paul DW; Fernandes SM; Hu Z; Stevens J; Guleria I; Kim HJ; Cantor H; Wucherpfennig KW; Brown JR; Ritz J; Zhang B
Nature; 2021 Feb; 590(7844):157-162. PubMed ID: 33361812
[TBL] [Abstract][Full Text] [Related]
4. Measurement of CD8+ and CD4+ T Cell Frequencies Specific for EBV LMP1 and LMP2a Using mRNA-Transfected DCs.
Sohn DH; Sohn HJ; Lee HJ; Lee SD; Kim S; Hyun SJ; Cho HI; Cho SG; Lee SK; Kim TG
PLoS One; 2015; 10(5):e0127899. PubMed ID: 26023769
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.
Kalra M; Gerdemann U; Luu JD; Ngo MC; Leen AM; Louis CU; Rooney CM; Gottschalk S
Cytotherapy; 2019 Feb; 21(2):212-223. PubMed ID: 30396848
[TBL] [Abstract][Full Text] [Related]
6. Latent Membrane Protein 1 (LMP1) and LMP2A Collaborate To Promote Epstein-Barr Virus-Induced B Cell Lymphomas in a Cord Blood-Humanized Mouse Model but Are Not Essential.
Ma SD; Tsai MH; Romero-Masters JC; Ranheim EA; Huebner SM; Bristol JA; Delecluse HJ; Kenney SC
J Virol; 2017 Apr; 91(7):. PubMed ID: 28077657
[TBL] [Abstract][Full Text] [Related]
7. T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells.
Nowakowska J; Stuehler C; Egli A; Battegay M; Rauser G; Bantug GR; Brander C; Hess C; Khanna N
Cytotherapy; 2015 Sep; 17(9):1280-91. PubMed ID: 26276009
[TBL] [Abstract][Full Text] [Related]
8. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes.
Khanna R; Burrows SR; Nicholls J; Poulsen LM
Eur J Immunol; 1998 Feb; 28(2):451-8. PubMed ID: 9521052
[TBL] [Abstract][Full Text] [Related]
9. A novel Epstein-Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy.
Cho HI; Kim UH; Shin AR; Won JN; Lee HJ; Sohn HJ; Kim TG
Br J Cancer; 2018 Feb; 118(4):534-545. PubMed ID: 29360818
[TBL] [Abstract][Full Text] [Related]
10. Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model.
Zhang B; Kracker S; Yasuda T; Casola S; Vanneman M; Hömig-Hölzel C; Wang Z; Derudder E; Li S; Chakraborty T; Cotter SE; Koyama S; Currie T; Freeman GJ; Kutok JL; Rodig SJ; Dranoff G; Rajewsky K
Cell; 2012 Feb; 148(4):739-51. PubMed ID: 22341446
[TBL] [Abstract][Full Text] [Related]
11. Primary CD4+ T-cell responses provide both helper and cytotoxic functions during Epstein-Barr virus infection and transformation of fetal cord blood B cells.
MacArthur GJ; Wilson AD; Birchall MA; Morgan AJ
J Virol; 2007 May; 81(9):4766-75. PubMed ID: 17314172
[TBL] [Abstract][Full Text] [Related]
12. CD4+ T cells inhibit growth of Epstein-Barr virus-transformed B cells through CD95-CD95 ligand-mediated apoptosis.
Wilson AD; Redchenko I; Williams NA; Morgan AJ
Int Immunol; 1998 Aug; 10(8):1149-57. PubMed ID: 9723701
[TBL] [Abstract][Full Text] [Related]
13. 'Off-the-shelf' allogeneic antigen-specific adoptive T-cell therapy for the treatment of multiple EBV-associated malignancies.
Sinha D; Srihari S; Beckett K; Le Texier L; Solomon M; Panikkar A; Ambalathingal GR; Lekieffre L; Crooks P; Rehan S; Neller MA; Smith C; Khanna R
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589524
[TBL] [Abstract][Full Text] [Related]
14. The impact of HLA class I and EBV latency-II antigen-specific CD8(+) T cells on the pathogenesis of EBV(+) Hodgkin lymphoma.
Jones K; Wockner L; Brennan RM; Keane C; Chattopadhyay PK; Roederer M; Price DA; Cole DK; Hassan B; Beck K; Gottlieb D; Ritchie DS; Seymour JF; Vari F; Crooks P; Burrows SR; Gandhi MK
Clin Exp Immunol; 2016 Feb; 183(2):206-20. PubMed ID: 26422112
[TBL] [Abstract][Full Text] [Related]
15. Identification and prevalence of CD8(+) T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2.
Meij P; Leen A; Rickinson AB; Verkoeijen S; Vervoort MB; Bloemena E; Middeldorp JM
Int J Cancer; 2002 May; 99(1):93-9. PubMed ID: 11948498
[TBL] [Abstract][Full Text] [Related]
16. CD4+ T cell responses in the immune control against latent infection by Epstein-Barr virus.
Paludan C; Münz C
Curr Mol Med; 2003 Jun; 3(4):341-7. PubMed ID: 12776989
[TBL] [Abstract][Full Text] [Related]
17. Triptolide inhibits proliferation of Epstein-Barr virus-positive B lymphocytes by down-regulating expression of a viral protein LMP1.
Zhou H; Guo W; Long C; Wang H; Wang J; Sun X
Biochem Biophys Res Commun; 2015 Jan; 456(3):815-20. PubMed ID: 25511707
[TBL] [Abstract][Full Text] [Related]
18. Mouse model of Epstein-Barr virus LMP1- and LMP2A-driven germinal center B-cell lymphoproliferative disease.
Minamitani T; Ma Y; Zhou H; Kida H; Tsai CY; Obana M; Okuzaki D; Fujio Y; Kumanogoh A; Zhao B; Kikutani H; Kieff E; Gewurz BE; Yasui T
Proc Natl Acad Sci U S A; 2017 May; 114(18):4751-4756. PubMed ID: 28351978
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
[TBL] [Abstract][Full Text] [Related]
20. CD27 is required for protective lytic EBV antigen-specific CD8+ T-cell expansion.
Deng Y; Chatterjee B; Zens K; Zdimerova H; Müller A; Schuhmachers P; Ligeon LA; Bongiovanni A; Capaul R; Zbinden A; Holler A; Stauss H; Hammerschmidt W; Münz C
Blood; 2021 Jun; 137(23):3225-3236. PubMed ID: 33827115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
